Why Scalable Cloud Data Platforms Are the Future of Biologic Drug Development

In this white paper Biomatters President Brett Ammundsen (PhD) discusses how a scalable cloud computing data platform that combines data management with scientific and data analysis workflows can drive competitive advantage and ultimately ensure the availability of more effective and safe antibody drugs for patients.

Download the whitepaper to discover:

  • Technological barriers to effective antibody discovery and how they can be addressed
  • How to reduce time to market, improve the ability to identify promising candidates and ‘fail early’ in the drug discovery phase
  • Why better data integration and collaboration minimizes the chance of missing quality antibody candidates

Download White Paper

Whitepaperthumb

About the Author

BRETT AMMUNDSEN, PhD, is President of Biomatters, the bioinformatics technology company that creates Geneious software to support biotechnology research. After gaining his PhD in chemistry and physics from Victoria University in Wellington, New Zealand, he worked as a research scientist in Montpellier, France, specializing in solid state molecular dynamics and computer modelling. He then returned to New Zealand to help incubate technology start-up businesses focusing on scientific applications. He has published more than 25 peer-reviewed papers and is co-author of several patents.